Study of the Usefulness of the Probiotic ‘Lactobacillus Reuteri’ in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice.

Overview

Helicobacter pylori is a Gram-negative bacterium with a helical bacillus shape that it's able to penetrate and colonize the stomach mucosal lining by infecting it. The eradication treatment of H. pylori is supported by numerous consensus groups worldwide and it is generally safe and well tolerated. Standard treatment is based on multiple drug regimens. However, its effectiveness has been increasingly compromised due to the emergence of resistant strains, as well as poor adherence to treatment. Therefore, it's proposed a randomized, double-blind, placebo-controlled study whose aims are: 1. Determine whether the combination of two probiotic strains of L reuteri (Gastrus) will improve gastrointestinal symptoms when associated with four-way therapy (of any type). 2. Prove whether supplementation with Gastrus (food supplement) versus Placebo is able to reduce the gastrointestinal adverse effects of quadruple eradication therapy. They will be determined by the GSRS gastrointestinal symptom scale in routine clinical practice.

Full Title of Study: “A Randomized, Double-blind, Placebo-controlled Study of the Usefulness of the Probiotic ‘Lactobacillus Reuteri’ in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: June 2018

Interventions

  • Dietary Supplement: GASTRUS
    • Gastrus will be given from the first day of eradication treatment to completion after 30 days of treatment
  • Other: PLACEBO
    • Placebo will be given from the first day of eradication treatment to completion after 30 days of treatment

Arms, Groups and Cohorts

  • Experimental: Treatment of quadruple eradication therapy with GASTRUS
  • Placebo Comparator: Treatment of quadruple eradication therapy with PLACEBO

Clinical Trial Outcome Measures

Primary Measures

  • Global score of gastrointestinal symptoms assessed according the GSRS scale
    • Time Frame: 30 days

Secondary Measures

  • Score obtained from each individual gastrointestinal symptom evaluated according the GSRS scale. Percentage of patients completing treatment
    • Time Frame: 60 days

Participating in This Clinical Trial

Inclusion Criteria

  • Patients attended at the clinic visit who present a positive diagnosis of H pylori infection using different diagnostic techniques (C13 breath test, histology, urease and / or H pylori antigen in stools). – Age between 18 and 65 years Exclusion Criteria:

  • Patients taking other probiotics 4 weeks prior to study start. – Patients who have previously received eradicating therapy. – Patients who are treated with NSAIDs, aspirin or other anti-inflammatory drugs either on an occasional basis (one week prior to the study) or on a chronic basis (3 weeks prior to inclusion). – Patients who have used oral antibiotics two weeks prior to inclusion. – Pregnancy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Dr. Luis Fernandez
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Dr. Luis Fernandez, PhD – Hospital Clínico Universitario de Valladolid
  • Overall Official(s)
    • Dr. Fernandez Dr. Jesus Barrio, Study Director, Managers study
  • Overall Contact(s)
    • Luis Fernandez, PhD, +34607537815, luisfernsal@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.